Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL | Q9Y232 | 2/20 | 0.39 |
| ▸ | CBX7 | O95931 | 1/20 | 0.39 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.39 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281821 | 0.98 | CDYL (0.41) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL281452 | 0.86 | CDYL (0.36) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL281967 | 0.84 | ALDH1A1 (0.37) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL282109 | 0.84 | CDYL (0.38) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL281862 | 0.82 | SCN9A (0.48) | ALDH1A1GAAMAPTSCN9A | |
| SCHEMBL3327230 | 0.81 | CBX7 (0.37) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL3008412 | 0.78 | ALDH1A1 (0.43) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL282112 | 0.77 | SCN9A (0.44) | SCN9A | |
| SCHEMBL3003189 | 0.76 | ALDH1A1 (0.45) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL14506540 | 0.76 | ALDH1A1 (0.61) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | claimed |
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-2073806-B1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-15 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-7935721-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-05-03 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | CDYL 3113/4885CBX7 2774/4885CDYL2 2917/4885 |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | CDYL 4277/4885CBX7 4548/4885CDYL2 4498/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | CDYL 4324/4885CBX7 4572/4885CDYL2 4582/4885 |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CDYL 4324/4885CBX7 4572/4885CDYL2 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.